We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.75%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
(+2.2%)
Cap. Flow
-$18.8M
Cap. Flow
% of AUM
-0.51%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$134M |
| 2 |
Eli Lilly
LLY
|
+$114M |
| 3 |
Hologic
HOLX
|
+$80.8M |
| 4 |
NeoGenomics
NEO
|
+$60.6M |
| 5 |
Biogen
BIIB
|
+$55.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$182M |
| 2 |
Intuitive Surgical
ISRG
|
+$103M |
| 3 |
AbbVie
ABBV
|
+$66.8M |
| 4 |
Medtronic
MDT
|
+$61.4M |
| 5 |
Bausch Health
BHC
|
+$60M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.32% |
| 2 | Technology | 1.61% |
| 3 | Financials | 0.8% |
| 4 | Consumer Discretionary | 0.14% |
| 5 | Miscellaneous | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$129B
| $192M | 5.18% |
950,000
+639,100
| +206% | +$134M |
2020 Q4
2 quarters
|
|
|
2
AbbVie
ABBV
$501B
| $167M | 4.52% |
1,484,400
-592,800
| -29% | -$66.8M |
2019 Q4
6 quarters
|
|
3
Arvinas
ARVN
$468M
| $143M | 3.86% |
1,854,000
+93,700
| +5% | +$6.5M |
2020 Q2
4 quarters
|
|
|
4
Eli Lilly
LLY
$1.12T
| $130M | 3.51% |
+565,500
| New | +$114M |
2021 Q2
0 quarters
|
|
5
Maravai LifeSciences
MRVI
$1.05B
| $124M | 3.34% |
2,963,545
+202,000
| +7% | +$7.83M |
2020 Q4
2 quarters
|
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $122M | 3.29% |
753,000
+277,300
| +58% | +$44.5M |
2020 Q3
3 quarters
|
|
7
Zentalis Pharmaceuticals
ZNTL
$212M
| $115M | 3.11% |
2,160,000
+896,700
| +71% | +$48M |
2020 Q2
4 quarters
|
|
8
Avantor
AVTR
$10.9B
| $113M | 3.05% |
3,180,000
-1,805,100
| -36% | -$58.4M |
2020 Q2
4 quarters
|
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $101M | 2.73% |
640,000
+62,100
| +11% | +$9.23M |
2021 Q1
1 quarter
|
|
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $85.7M | 2.32% |
882,500
-167,300
| -16% | -$13.6M |
2020 Q1
5 quarters
|
|
|
11
DELISTED
Hologic
HOLX
| $80.7M | 2.18% |
+1,208,800
| New | +$80.8M |
2021 Q2
0 quarters
|
|
12
Syndax Pharmaceuticals
SNDX
$1.22B
| $79.2M | 2.14% |
4,615,000
+769,000
| +20% | +$14.1M |
2020 Q2
4 quarters
|
|
13
DELISTED
ESSA Pharma
EPIX
| $78.6M | 2.12% |
2,750,000
-90,000
| -3% | -$2.62M |
2020 Q3
3 quarters
|
|
14
DELISTED
Exact Sciences
EXAS
| $73.3M | 1.98% |
590,000
-8,000
| -1% | -$955K |
2020 Q4
2 quarters
|
|
|
15
Medtronic
MDT
$122B
| $66.4M | 1.79% |
535,000
-489,200
| -48% | -$61.4M |
2020 Q2
4 quarters
|
|
16
Neurocrine Biosciences
NBIX
$13.9B
| $66.3M | 1.79% |
681,000
+159,600
| +31% | +$15.3M |
2020 Q4
2 quarters
|
|
17
Nuvation Bio
NUVB
$1.67B
| $64.9M | 1.75% |
6,966,376
-555,565
| -7% | -$6.34M |
2021 Q1
1 quarter
|
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $64.3M | 1.74% |
943,000
+44,450
| +5% | +$2.9M |
2020 Q4
2 quarters
|
|
|
19
Biogen
BIIB
$34.8B
| $63.7M | 1.72% |
+183,900
| New | +$55.7M |
2021 Q2
0 quarters
|
|
|
20
NeoGenomics
NEO
$2.22B
| $61.7M | 1.67% |
+1,367,000
| New | +$60.6M |
2021 Q2
0 quarters
|
|
21
Intellia Therapeutics
NTLA
$1.59B
| $61.5M | 1.66% |
+380,000
| New | +$29.6M |
2021 Q2
0 quarters
|
|
22
NovaBridge Biosciences American Depositary Shares
NBP
$149M
| $61.2M | 1.65% |
729,000
-600,000
| -45% | -$39.6M |
2020 Q3
3 quarters
|
|
23
DELISTED
CATALENT, INC.
CTLT
| $58.4M | 1.58% |
540,000
-20,000
| -4% | -$2.14M |
2020 Q3
3 quarters
|
|
24
Shattuck Labs
STTK
$555M
| $56.2M | 1.52% |
1,940,200
+609,815
| +46% | +$17.8M |
2020 Q4
2 quarters
|
|
25
Centene
CNC
$34.8B
| $54.8M | 1.48% |
+751,200
| New | +$51.5M |
2021 Q2
0 quarters
|
|
Similar funds
ANB
CWM
RIP
TAM
B
PWS
LWP
TAA
Avidity Partners Management's Q2 2021 Portfolio in Review
As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
- Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
- Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
- Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
- Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
- Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
- Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
- Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.
Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.